What Doses Does Tirzepatide Come In?

Tirzepatide represents a dual-action medication that activates both GLP-1 and GIP receptor pathways in the body. PlexusDx offers compounded tirzepatide injections and oral formulations across multiple dose strengths to support personalized treatment plans. This guide explains the complete tirzepatide dosing landscape and how clinicians match doses to individual patient needs.

What Is Tirzepatide and How Does It Work?

Tirzepatide functions as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual mechanism distinguishes tirzepatide from single-pathway GLP-1 medications, allowing it to influence appetite regulation through two complementary biological channels simultaneously.

The medication slows gastric emptying, which means food moves through the digestive system more gradually and creates prolonged satiety signals to the brain. Additionally, tirzepatide enhances the pancreas's natural insulin secretion when blood glucose rises, helping regulate postprandial blood sugar spikes.

Clinical research demonstrates that the dual GIP/GLP-1 approach produces greater weight reduction than single GLP-1 agents alone. The SURMOUNT trial series showed tirzepatide recipients achieved reductions up to 22% of baseline body weight at the highest maintenance doses.

Complete Tirzepatide Dosing Schedule: Available Strengths

Tirzepatide comes in five FDA-approved injection dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, and 15 mg. Each strength is administered as a once-weekly subcutaneous injection, typically delivered via pre-filled pen devices. PlexusDx sources compounded tirzepatide from licensed 503A compounding pharmacies and offers both injectable and oral formulations at multiple strength levels.

The standard dosing protocol begins with 2.5 mg once per week as the starting dose. This conservative initial strength allows the body to acclimate to the medication's effects while minimizing gastrointestinal side effects. Starting low and titrating upward remains the evidence-based approach across all tirzepatide treatment plans.

Dose escalation typically occurs every four weeks during the titration phase. Patients advance from 2.5 mg to 5 mg, then to 7.5 mg, continuing upward based on tolerability and therapeutic response. Most patients reach a 10 mg or 15 mg maintenance dose, though individual targets vary based on clinical response and patient tolerance.

Initial Dosing Phase: Starting Tirzepatide Treatment

All tirzepatide treatment protocols begin with a 2.5 mg injection once weekly, regardless of the patient's target maintenance dose. This starting strength allows the digestive system and metabolic pathways to adapt gradually to the medication's dual receptor activation. Beginning at this modest dose significantly reduces early nausea and GI adjustment symptoms.

During the first four weeks of treatment, patients receive education on injection technique, timing consistency, and expected timeline for dose progression. The 2.5 mg dose itself produces modest appetite suppression and modest improvements in postprandial glucose control, providing immediate therapeutic benefit while the body accommodates to the medication.

Most patients tolerate the 2.5 mg starting dose well, with minimal side effects beyond occasional mild nausea. After one full week at the initial dose, patients are typically prepared for dose escalation discussions with their care team. Advancement to 5 mg occurs at the four-week mark if the patient demonstrates adequate tolerance and readiness for increased medication intensity.

Maintenance Dosing and Target Strength Selection

Maintenance tirzepatide doses range from 5 mg to 15 mg once weekly, with 10 mg and 15 mg representing the most commonly prescribed maintenance targets. The SURMOUNT clinical trial data showed that 10 mg and 15 mg doses produced the most substantial sustained weight reduction over 72 weeks of continuous therapy. However, individual response varies significantly based on genetic predispositions, baseline metabolism, and concurrent health conditions.

PlexusDx's Precision Peptide Genetic Test examines key variants affecting tirzepatide response, including GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609 polymorphisms. These genetic insights guide selection of optimal maintenance target doses and help predict likelihood of response at different strength levels. Patients with favorable genetic markers may achieve maximum benefit at lower maintenance doses, while others may require higher strengths for optimal outcomes.

Once a patient reaches maintenance dose, the injection protocol remains consistent at once-weekly administration. Maintenance continues indefinitely as long as the patient tolerates the dose and achieves therapeutic goals. Some patients maintain excellent results at 7.5 mg, while others require the full 15 mg strength to achieve desired weight loss or glycemic control outcomes.

Tirzepatide Dosing for Weight Loss vs. Diabetes Management

Tirzepatide dosing strategies differ slightly depending on treatment indication, though the foundational escalation protocol remains identical. For weight loss in patients without type 2 diabetes, the medication works primarily through appetite suppression and metabolic rate enhancement. The SURMOUNT trials in non-diabetic populations showed that doses of 10 mg and 15 mg weekly produced mean weight reductions of approximately 20% and 22% respectively over 72 weeks.

In type 2 diabetes patients, tirzepatide's blood glucose-lowering effects become the primary therapeutic target alongside weight reduction. The medication's GIP pathway activation enhances endogenous insulin secretion in response to food intake, creating more physiologic glucose control. Diabetes patients may achieve therapeutic benefit at lower maintenance doses (5 mg or 7.5 mg) compared to weight-loss-only patients, as the dual pathway activation creates superior glycemic control even at intermediate doses.

PlexusDx pricing for compounded tirzepatide injections ranges from $249 monthly depending on dose strength and formulation, while oral tirzepatide extends from $279 monthly. Both injectable and oral formats follow identical dose escalation schedules, allowing patients to select delivery method based on personal preference and compliance patterns. HSA and FSA funds cover both formats, and no membership or insurance is required for treatment access across all 50 states.

Frequently Asked Questions About What Doses Does Tirzepatide Come In?

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.